MEKanistic Therapeutics, Inc.
MEKanistic Therapeutics, Inc. is a pioneering biotech company based in Minneapolis, MN, dedicated to developing innovative cancer therapies. Their breakthrough approach involves the use of a single-molecule, dual inhibitor drug that effectively blocks key pathways responsible for cancer cell growth, resulting in unparalleled tumor shrinkage in preclinical studies. With a world-class team of experts and a strong focus on KRAS-mutant cancer therapies, MEKanistic is at the forefront of advancing the field of kinase inhibitors.
Backed by Invenshure, a venture studio with a proven track record in building impactful biotech companies, MEKanistic is committed to creating meaningful returns for investors while making a significant impact on the lives of patients. Their pipeline includes promising compounds such as MTX-531 and MTX-241F, which are undergoing various stages of development, aiming to bring breakthrough therapies to market and improve outcomes for cancer patients worldwide.
Generated from the website
Also at this address
You might also like
Partial Data by Infogroup (c) 2024. All rights reserved.
